Company Overview
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
Recent Developments
- Dec 2025 Revenue of $31.37M (-27.5% YoY); net profit $-231.96M.
- Trailing 12 Months Year-on-year growth — revenue +161.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 1.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 1.94% |
| 1 Year: | 161.70% |
Stock Price Performance
| 1 Year: | +36.18% |
| 6 Months: | -13.11% |
| 3 Months: | -3.42% |
| 1 Month: | +6.29% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)51.03 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 26.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EYPT EyePoint, Inc. R2K | 13.85 | -3.95 | $1.16B | 0.00% | -74.45% | -102.71% | 1.94% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 277.00K | 5.97M | 590.00K | 701.00K | 385.00K | 933.00K | 928.00K | 715.00K | 486.00K | 2.44M | 2.01M | 7.21M | 2.51M | 8.63M | 7.49M | 4.12M | 15.70M | 7.32M | 9.01M | 9.06M | 9.29M | 11.56M | 10.01M | 7.68M | 9.11M | 15.20M | 11.68M | 9.48M | 10.52M | 24.45M | 5.33M | 966.00K | 696.00K |
| Operating Income | -4.12M | -5.05M | -5.20M | -4.98M | -5.24M | -5.10M | -6.46M | -7.19M | -94.00K | -5.16M | -6.14M | -6.01M | -5.81M | -4.68M | -9.78M | -13.55M | -11.01M | -14.65M | -10.16M | -14.06M | -8.98M | -11.44M | -11.15M | -1.96M | -10.94M | -10.98M | -15.31M | -18.28M | -19.22M | -18.40M | -21.55M | -22.76M | -14.40M | -33.32M | -34.55M | -32.75M | -48.84M | -62.23M | -62.02M | -87.23M |
| Net Income | -4.08M | -5.00M | -5.15M | -4.93M | -5.19M | -5.04M | -6.39M | -7.16M | -67.00K | -5.14M | -6.12M | -5.98M | -5.78M | -6.98M | -34.43M | -33.13M | -11.59M | -19.24M | -11.50M | -15.65M | -10.41M | -13.17M | -12.95M | -3.80M | -12.28M | -10.01M | -16.70M | -20.98M | -19.41M | -18.42M | -21.16M | -22.92M | -12.61M | -29.28M | -30.83M | -29.36M | -45.20M | -59.43M | -59.73M | -84.83M |
| Diluted EPS | -0.14 | -0.17 | -0.17 | -0.17 | -0.18 | -0.15 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.35 | -0.58 | -0.56 | -0.52 | -0.49 | -0.56 | -0.61 | -0.33 | -0.55 | -0.58 | -0.54 | -0.65 | -0.85 | -0.85 | -0.99 |
| R&D Expense | 2.77M | 3.34M | - | 3.48M | 3.72M | 3.07M | - | 4.18M | 3.17M | 3.32M | - | 3.82M | 4.27M | 3.33M | 4.76M | 6.23M | - | 3.80M | 3.96M | 3.48M | - | 4.85M | 3.28M | 4.09M | 5.48M | 5.61M | 8.50M | 9.95M | 12.99M | 11.16M | 13.62M | 15.73M | 17.36M | 30.14M | 29.82M | 29.54M | 58.57M | 55.50M | 47.75M | 72.15M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23.05M | 4.96M | 3.53M | 2.14M | 3.47M | 26.57M | 1.62M | 7.54M | 2.96M | 4.57M | 20.36M | 34.44M | 36.94M | 41.40M | 46.02M | 43.27M | 31.37M |
| Operating Income | 9.09M | -10.00M | -25.21M | -12.03M | -13.49M | 6.42M | -21.77M | -18.58M | -26.27M | -39.02M | -47.86M | -37.29M | -55.28M | -99.64M | -75.07M | -145.85M | -243.43M |
| Net Income | 8.75M | -8.63M | -24.84M | -11.90M | -13.36M | 6.35M | -21.55M | -18.48M | -53.17M | -86.12M | -56.79M | -45.39M | -58.42M | -102.25M | -70.80M | -130.87M | -231.96M |
| Diluted EPS | 0.46 | -0.44 | -1.19 | -0.52 | -0.49 | 0.21 | -0.68 | -0.52 | - | - | - | - | -2.03 | -2.74 | -1.82 | -2.32 | -3.17 |
| R&D Expense | 6.99M | 6.86M | 7.04M | 7.00M | 9.57M | 12.09M | 14.38M | 14.88M | 16.18M | 18.50M | 15.37M | 17.42M | 28.50M | 49.64M | 64.66M | 132.93M | 221.04M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 47.11M | 20.60M | 16.25M | 22.67M | 32.37M | 31.62M | 18.68M | 71.67M | 78.17M | 72.97M | 91.72M | 263.37M | 180.36M | 355.18M | 418.46M | 364.00M |
| Total Equity | 23.54M | 33.04M | 37.43M | 13.64M | 7.70M | 14.92M | 23.37M | 20.88M | 13.34M | 11.69M | 37.63M | 8.33M | 18.54M | 184.38M | 96.37M | 266.32M | 336.50M | 306.11M |
| Cash & Equivalents | 6.90M | 15.51M | 12.91M | 4.62M | 6.90M | 15.33M | 19.12M | 15.31M | 16.90M | 38.78M | 45.26M | 22.21M | 44.91M | 178.59M | 95.63M | 281.26M | 99.70M | 101.82M |
| Long Term Debt | - | - | - | - | - | - | - | - | 0 | 17.31M | 17.62M | 47.22M | 37.98M | 36.56M | 29.31M | - | - | - |
| Total Liabilities | - | - | 9.68M | 6.96M | 8.55M | 7.75M | 9.00M | 10.74M | 5.34M | 59.98M | 40.53M | 64.64M | 73.18M | 78.99M | 83.99M | 88.86M | 81.96M | 57.88M |
| Current Liabilities | - | - | 5.03M | 3.18M | 3.30M | 2.13M | 3.35M | 5.09M | 5.29M | 21.66M | 21.46M | 11.52M | 14.89M | 23.66M | 34.54M | 63.26M | 49.05M | 37.02M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 9.90M | -3.17M | -9.00M | -8.74M | - | - | -16.32M | -20.49M | -21.91M | -56.70M | -14.44M | -50.10M | -65.00M | 1.88M | -126.23M | -240.11M |
| Investing Cash Flow | -2.07M | -9.50M | 606.00K | 6.36M | - | - | -4.46M | 13.58M | -16.89M | -213.00K | -362.00K | -33.12M | -17.27M | -3.31M | -219.35M | 68.58M |
| Financing Cash Flow | 802.00K | 10.06M | 114.00K | 4.67M | - | - | 16.99M | 8.50M | 60.67M | 33.86M | 37.49M | 216.90M | -690.00K | 187.07M | 164.02M | 173.65M |
| Capital Expenditure | -15.00K | -133.00K | -405.00K | -68.00K | -248.00K | -161.00K | -113.00K | -147.00K | -108.00K | -213.00K | -362.00K | -156.00K | -2.15M | -3.48M | -4.05M | -3.28M |
| Free Cash Flow | 9.88M | -3.30M | -9.41M | -8.81M | - | - | -16.43M | -20.64M | -22.02M | -56.91M | -14.80M | -50.25M | -67.16M | -1.61M | -130.28M | -243.39M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 39.4% | -201.5% | -715.0% | -561.4% | -388.4% | 24.2% | -1,344.1% | -246.4% | -887.3% | -853.6% | -235.0% | -108.3% | -149.6% | -240.6% | -163.1% | -337.1% | -776.0% |
| Net Margin % | 38.0% | -173.8% | -704.3% | -555.3% | -384.5% | 23.9% | -1,330.1% | -245.2% | -1,795.7% | -1,884.2% | -278.9% | -131.8% | -158.1% | -247.0% | -153.8% | -302.4% | -739.4% |
| ROE % | 26.5% | -23.0% | -182.1% | -154.5% | -89.5% | 27.2% | -103.2% | -138.6% | -455.0% | -228.9% | -681.8% | -244.8% | -31.7% | -106.1% | -26.6% | -38.9% | -75.8% |
| ROCE % | - | -23.8% | -144.7% | -92.9% | -65.7% | 22.1% | -82.1% | -138.8% | -52.5% | -68.8% | -77.9% | -48.5% | -23.1% | -68.3% | -25.7% | -39.5% | -74.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Suvretta Capital Management, LLC | 9.90% | 8.30M | $113.91M |
| 2 | Cormorant Asset Management, LP | 9.86% | 8.27M | $113.48M |
| 3 | Blackrock Inc. | 8.56% | 7.18M | $98.54M |
| 4 | Federated Hermes, Inc. | 6.76% | 5.67M | $77.84M |
| 5 | Franklin Resources, Inc. | 6.02% | 5.05M | $69.32M |
| 6 | Janus Henderson Group PLC | 4.30% | 3.60M | $49.44M |
| 7 | Vanguard Capital Management LLC | 4.25% | 3.56M | $48.87M |
| 8 | Adage Capital Partners GP L.L.C. | 3.94% | 3.30M | $45.31M |
| 9 | Paradigm Biocapital Advisors LP | 3.75% | 3.14M | $43.15M |
| 10 | Commodore Capital Lp | 3.37% | 2.83M | $38.79M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EYPT
EYPT Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9leU4zWV9Qa19jYURyUFRUWXppN0xkOExWdm9kWXdfNlUwaC1HN0dxTUhoMW5UNk1pX1pQSzBKemRmU2pNYzB4bzVJRkx2TDVoa0lObFNFbGUzZjB4MmlkaE5QZkRqLW1hS0hRcHp4Sk1wdDlKLU5kSVh3?oc=5" target="_blank">EYP…
Renowned retina specialist Tarek S. Hassan joins EyePoint ahead of key DURAVYU trial readout - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQdEhfcEZkSUFxOGZkM3ZxM1ItUHpibmRGQWlLeWU4QnZ2TjEyWWFodWZyN2tUWUdqanJlS3ZjMXhfYzZJNkg3TFNOS2UyQ1o0YmVsY3pfUzRldXRzME9iNW1OYUo2M1RLNEpjRzdJNHd6VTZfb0ZROGpyWUZFenVjb2NMTW5lUTNpSFNYa2…
EyePoint (EYPT) Adds Retina Leadership, Is The 64% Undervaluation Case Convincing? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxQdEpiX2ROVXlQa0U5UVM4S1Y0WFRJYXJYV2lwcFRrdTRNME9ZLW5waG5MbkdGZ1dLVjB0ZnF4N1plZ3dXZ0paQjJwLVh1Q05wdEYzMkFEZ1cxRUNQdWlIVVJteWZJTlFuRWhXbjB5YVFycG1RNndDQ0NzcVhVUnR2NDMtWHM0WDdsRUJLUm…
Assessing EyePoint (EYPT) Valuation After Recent Share Price Weakness - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPSU9WVUhSTHRLZEpJWUV5YzZvNGpLdTZnWDZSV3RQOEJtZWh1VTBPOXBpaUtkOW1iYlhMVThsUy1DWTczLVRHTU5HbFVqUDVLZDNGRzQ1M0tNMmExRWJkdW80TF94dFI4VDgzbmg4cFN0SXA3MGl3c0xXOERCTXdlVlUwd0hLUGRmS1ZzM2…
Mizuho Securities Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $36 - Moomoo
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQeWJSZVowMnFXSFR5ZEx3aGYyd1VPNVVQQ0doU2VXRXEtWGZGb2QwWGFaZDVuVTlFaE9YQ2V3aEYxTldDR0xIUWlRcTVJWkVUd05hMTJ6UDhrNTlnRTIzV1NiRXRkSHZZNzNZNjJGbW1vRWE3QS00ZE4yZTJjZ2R2VzZMNkxVcGMtS3RUUz…
EyePoint, Inc. (EYPT) CEO exercises RSUs, with shares withheld for taxes - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPczJfdWZfcGJ4WnpCUjBUdDF5Z0xUQ09jX2JwcWdpOTFoZ0xBYUh4LXVOWHpUY3VpZG51a2ZNTnBHdmtoVWV1eHRTTDhZS1dlamFsLWgycks1YXgyekZXT2U2MEdiVUZ0Y2pyQUY5VlZ3YnpYekN0c1hGbjBGbW1zVGU4eTgzcTI1cTZTdD…
EYPT — Frequently Asked Questions
What is the current share price of EyePoint, Inc. (EYPT)?
As of 2026-07-15 16:51 PDT, EyePoint, Inc. (EYPT) trades at $13.85 on NasdaqGM. Its 52-week range is $9.71 to $18.85.
What is the market capitalisation of EYPT?
EyePoint, Inc. (EYPT) has a market capitalisation of $1.16B on NasdaqGM.
What is the P/E ratio of EYPT?
EYPT trades at a trailing price-to-earnings (P/E) ratio of -3.95. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 34.67.
What is the return on equity (ROE) of EYPT?
EYPT has a return on equity (ROE) of -102.71%. Its return on capital employed (ROCE) is -74.45%.
Is EYPT a good stock to buy?
This page provides a data-driven analysis of EyePoint, Inc. (EYPT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.